Cancer is the most expensive and lethal non-communicable diseases globally. The management of cancer mainly relies upon the availability and affordability of anticancer medicines. In recent years, the emergence of newer anticancer medicines has rapidly and substantially caused an expansion not only in the repertoire but also in the average per month cost of these therapeutic agents. Cancer treatment demands substantial cost thus posing huge burden on patient and healthcare system in Bangladesh and globally.
To manufacture and market the anticancer products, Pharmasia has decided to set up a new manufacturing plant as per its business expansion plan. Pharmasia’s oncology facility will be combined with state-of-the-art organizational procedures and technical standards in accordance with current industry guidance. The goal is to help ensure the greatest possible reduction of different modes of potential cross contamination – whether it be (i) transfer by airborne migration of particulates, (ii) mechanical transfer from operators or equipment, (iii) residual carry-over due to inadequate cleaning, or (iv) mix-up by using wrong products, ingredients or equipment. Dedicated or single-use equipment is sometimes used to further reduce the low risk of cross-contamination within the risk-based approach.